New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How do you manage a possible autoimmune sialadenitis arising from checkpoint inhibitor therapy?

1 Answers

Mednet MemberInvited Expert
Rheumatology · Ohio State University

This is a great question and a common clinical scenario in patients receiving immune checkpoint inhibitors. In my experience, severe sicca symptoms from immunotherapy are often not classic primary Sjögren's syndrome, despite some overlapping features. Rather, this appears to be an acute T-cell-media...

How do you counsel patients with GCA on the benefits of steroids who have already experienced vision loss?

4
6 Answers

Mednet MemberInvited Expert
Neurology · University of Iowa

I first tell the patient they are at considerable risk for further visual loss in the same eye or the other eye over the next 1-2 weeks. I also let them know that, even though their risk of visual loss has been reduced, their best option for preventing further visual loss is immediately starting hig...

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

1
4 Answers

Mednet Member
Rheumatology · Leiden University Medical Center

Many trials have a placebo-controlled period of 12-24 weeks. Thereafter, all patients receive active treatment. Even if the original treatment allocation remains unknown to the patient and doctor, they know that from that moment on, everyone receives active treatment. This will have an influence on ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

3 Answers

Mednet Member
Rheumatology · Mayo Clinic Jacksonville

This is an extremely important question and one that is likely to change as new data becomes available. It is important to remember that psoriatic arthritis (PsA) is a complex and heterogeneous disease and a single approach does not work for every patient. Based on the ACR/NPF 2019 PsA treatment gui...

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

3 Answers

Mednet Member
Rheumatology · Leiden University Medical Center

The dependence on the use of systemic glucocorticoids may indeed be a good reason to change treatment. Especially in patients with psoriatic arthritis. So, if patients are unable to stop systemic glucocorticoids and there are still treatment options for the patient, this could be tried. It is diffic...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

In a young patient who was vaccinated against chickenpox as a child (no previous varicella infection), should the patient receive a shingles vaccine prior to starting Rinvoq?

2
3 Answers

Mednet MemberInvited Expert
Gastroenterology · Northwestern Medicine

Yes. The vaccines are different and current vaccine is to prevent zoster for patients who have been previously exposed to varicella or vaccinated for varicella.

What would be the next recommended treatment option for a patient with VEXAS syndrome and a significant history of coronary artery disease who developed cytopenias and was unable to tolerate tocilizumab?

1 Answers

Mednet Member
Rheumatology · Baptist Health Jacksonville Rheumatology

Seems like a very tough patient. If the patient has myelodysplastic syndrome or another hematologic malignancy (given he has cytopenias, there is a good likelihood), one option is to send him to hematology for treatment with azacitidine. In the French VEXAS study group, there was a 41% inflammatory ...

What therapies do you offer patients who have osteoporosis and CKD and have had adverse reactions to several oral bisphosphonate therapies and denosumab?

1 Answers

Mednet MemberInvited Expert
Rheumatology · Icahn School of Medicine at Mount Sinai

Without further details as to the severity of CKD, the severity of the osteoporosis, and the specific intolerance issues with denosumab (and/or BPs), this is a very difficult question to provide specific advice. Some general comments can be offered: CKD stage 4-5 is essentially without fracture data...

What treatment options would you consider for a patient with seronegative inflammatory arthritis in setting of history of liver transplant on mycophenolate mofetil and cyclosporine?

3 Answers

Mednet MemberInvited Expert
Rheumatology · Johns Hopkins School of Medicine

Some of this depends on how far out they are from transplant and the preference of their transplant team. For a patient with RA and a liver transplant, I was able to ask the transplant hepatologist to switch to azathioprine instead of mycophenolate, which was more helpful for the joints. Cyclosporin...